Citadel Advisors
ATXI

Citadel Advisors’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Citadel Advisors’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,182
Closed -$14.4K – 15622
2023
Q4 		$14.4K Buy
+1,182
New +$27.7K ﹤0.01% 12878
2022
Q4 		– Sell
-478
Closed -$362K – 15580
2022
Q3 		$362K Buy
+478
New +$153K ﹤0.01% 9171
2022
Q2 		– Sell
-105
Closed -$57K – 14334
2022
Q1 		$57K Buy
105
+83
+377% +$62K ﹤0.01% 12709
2021
Q4 		$22K Sell
22
-2
-8% -$2.89K ﹤0.01% 13568
2021
Q3 		$41K Buy
+24
New +$49.6K ﹤0.01% 13466

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's ATXI Position: Q1 2024 in Review

Citadel Advisors sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2024, closing a stake of 1,182 shares — an estimated $14.4K sold.

Citadel Advisors first reported a position in ATXI in Q3 2021 and held it in 5 quarters. The position peaked at $362K in Q3 2022. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2024.

  • Citadel Advisors reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,182 Avenue Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.4K.
  • Citadel Advisors first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
  • Citadel Advisors's Avenue Therapeutics, Inc. Common Stock position peaked at $362K in Q3 2022.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.